Granted Patent B2

US 12,415,839 · App. 17/058,367 · Granted Sep 16, 2025

Inventors: Mojca Lunder (Ljubljana, SI); Borut Štrukelj (Ljubljana, SI); Peter Korošec (Ljubljana, SI); Ana Koren (Ljubljana, SI); Jernej Luzar (Ljubljana-Črnuče, SI); Abida Zahirović (Sarajevo, SI)

Assignees: Univerza v Ljubjani; University Clinic of Respiratory and Allergic Diseases

C07K14/415A61K9/0019A61K9/0053A61K39/35A61P37/08A61K38/00A61K2039/577

Abstract

Claims (15)

1. A method for treatment of peanut allergy, for prevention of systemic adverse events during peanut immunotherapy or for prevention of allergic reaction during medical interventions with peanut allergens or peanut extracts, said method comprising administering a therapeutic effective amount of a pharmaceutical composition comprising:

at least one peptide having the following structure:

Z-X1-His-Pro-Arg-X2-X3-X4-X5-X6-X7-X8-X9-U  (Structure I)

wherein:

X1 is a polar or charged amino acid: X2 is a hydrophobic, aromatic amino acid;

X3 may or may not be present, but if present it is a polar or non-polar amino acid;

X4 may or may not be present, but if present it can be any amino acid;

X5 may or may not be present, but if present it is a charged or polar amino acid;

X6 may or may not be present, but if present it is a polar amino acid;

X7 may or may not be present, but if present it is a polar or charged amino acid;

X8 may or may not be present, but if present it is a non-polar or polar amino acid;

X9 may or may not be present, but if present it is a non-polar amino acid;

Z is a hydrogen atom replacing the N-terminal amino group or an N-terminal amino group, or a stability enhancing moiety, bound either to the N-terminal amino group or directly to the alpha C-atom of the N-terminal residue;

U is a hydrogen atom replacing the C-terminal carboxyl group or a C-terminal carboxyl group, or is a linker or a stability enhancing moiety, bound either to the C-terminal carbonyl group or directly to the alpha C-atom of the C-terminal residue, or the retro-inverso analogue of the peptide, and optionally at least one pharmaceutically acceptable excipient,

wherein the at least one peptide is selected from the group consisting of SEQ ID NO: 1-10.

Assignments (2)

Continuity (1)

References Cited (27)